Vaccine Trial Sparks Outrage

A controversial hepatitis B vaccine trial in Guinea-Bissau has been given the go-ahead, despite widespread criticism. The trial will withhold the vaccine from thousands of newborns.

The University of Southern Denmark has approved a trial that will enroll 14,000 infants in Guinea-Bissau, giving the hepatitis B vaccine to half of the babies at birth and withholding it from the others for the first six weeks of life.

The trial has been criticized by health experts, including Paul Offit, an infectious disease physician at Children's Hospital of Philadelphia, who says it is 'wholly unethical' and should not be allowed.

The US Centers for Disease Control and Prevention (CDC) is providing $1.6 million in funding for the trial, which has been touted by Robert F Kennedy Jr, a longtime vaccine opponent.

The trial has sparked international outcry, with many criticizing the decision to withhold a life-saving vaccine from thousands of newborns.

Guinea-Bissau has one of the highest rates of hepatitis B infection in the world, with nearly one in five people infected.

The World Health Organization recommends vaccinating newborns against hepatitis B, but Guinea-Bissau does not currently have a national vaccination program in place.

The trial's lead researchers, Christine Stabell Benn and Peter Aaby, have defended their study, saying that no child enrolled in the trial will receive fewer vaccines than under current national policy in Guinea-Bissau.

Key facts

  • 14,000 infants in Guinea-Bissau will be enrolled in the trial
  • Half of the babies will receive the hepatitis B vaccine at birth, while the other half will not receive it for the first six weeks of life
  • The trial is being funded by the US Centers for Disease Control and Prevention (CDC) with $1.6 million
  • Guinea-Bissau has one of the highest rates of hepatitis B infection in the world

Three perspectives

Neutral

The trial has sparked a heated debate about the ethics of vaccine research in developing countries. As the trial moves forward, it will be important to monitor its progress and ensure that the rights of the participants are protected.

Positive

The trial's researchers argue that it will provide valuable information about the safety and effectiveness of the hepatitis B vaccine. If successful, the trial could lead to improved vaccination programs in Guinea-Bissau and other developing countries.

Negative

Critics of the trial argue that it is unethical to withhold a life-saving vaccine from thousands of newborns. The trial's funding by the CDC has also raised questions about the agency's priorities and commitment to global health security.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition